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Background: Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning)
for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce the
relapse rate of the underlying disease, but it might simultaneously increase the transplant-related mortality
including the mortality of infections. To explore whether intensified conditioning affected Epstein-Barr virus (EBV)
and cytomegalovirus (CMV) infections, 185 patients undergoing allo-HSCT were enrolled.
Methods: A total of 104 cases received standard and 81 intensified conditioning. Cyclosporine A (CsA) withdrawal
and/or donor lymphocyte infusion (DLI) were conducted in high-risk patients. The EBV-DNA and CMV-DNA levels of
blood were monitored regularly by quantitative real-time polymerase chain reaction (RQ-PCR) and immune
reconstitution of recipients were analyzed by flow cytometry.
Results: The 3-year cumulative incidence of EBV viremia, EBV-associated diseases and mortality of EBV-associated
diseases were 25.3%± 4.6%, 10.5% ± 3.4% and 0.0%± 0.0% in the standard group, compared with 45.6%± 6.5%,
26.0% ±5.3% and 7.3%± 3.1% in the intensified group (P= 0.002, P= 0.002, P= 0.008). The 3-year cumulative
incidence of CMV viremia and CMV-associated diseases, mortality of CMV-associated diseases and incidence of
bacterial and fungal infections were similar between the two groups (P= 0.855, P= 0.581, P= 0.933, P= 0.142,
P= 0.182, respectively). Multivariate analysis showed that intensified conditioning was one of the risk factors for EBV
viremia and EBV-associated diseases (P= 0.037, P= 0.037), but it had no effects on CMV infections. The percentage
of CD4+ T cells and CD4+/CD8+ ratio at 3 months post-transplantation were lower in the intensified group
(P= 0.032, P= 0.022). The 3-year OS and DFS in the standard group were 62.2%± 5.8% and 60.6%± 5.6%, compared
with 51.6%± 6.2% and 51.1%± 5.9% in the intensified group (P= 0.029, P= 0.063).
Conclusions: Intensified conditioning represents a promising approach for high-risk hematological malignancies,
although it affects early immune reconstitution of recipients and increases the incidence and mortality of EBV
infections.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a curative approach for hematological
malignancies [1,2]. Besides graft-versus-host disease
(GVHD), the two main causes of death after allo-
HSCT remain relapse of malignancy and infections
[3,4]. The relapse rate exceeds 50% in patients with re-
fractory hematological malignancies with a standard
myeloablative (MA) regimen consisting of total body
irradiation (TBI)/busulfan (Bu) combined with cyclo-
phosphamide (CY) [5]. Reduced-intensity conditioning
(RIC) regimens have been advocated to reduce
transplantation-associated toxicity in elderly or medic-
ally unfit patients [6,7]; however, disappointing results
have been reported with RIC transplantation in
patients with refractory hematological malignancies
[8,9]. Some studies suggested that intensified condi-
tioning regimens, which increased the intensity of
standard myeloablative conditioning, could reduce
tumor relapse, but it might simutaneously increase the
transplant-related mortality (TRM) including the mor-
tality of infections [10-12]. Therefore, overall survival
(OS) did not improve significantly. To improve the
outcomes of allo-HSCT for refractory hematological
malignancies, we introduced a strategy of sequential
intensified conditioning and early rapid tapering of
prophylactic immunosupressants therapy for GVHD
during the early stage after transplantation [13]. The
results of this trial suggested that this strategy might
reduce tumor relapse. Moreover, the nonrandomized
data suggested that this strategy did not increase the
incidence and mortality of bacterial and fungal infec-
tions [13], but the effect of this strategy on opportunis-
tic viral infections needed further investigation.
Opportunistic viral infections, especially Epstein Barr
virus (EBV) and cytomegalovirus (CMV) infections are
one of the common complications after allo-HSCT. Both
primary infections and reactivations of EBV and CMV
may result in life-threatening diseases in recipients of
allo-HSCT [14-17]. The occurrence of EBV and CMV
infections and reactivations is influenced by several fac-
tors and closely related to the immune function [18-21].
Some studies showed that the intensity of conditioning
might affect immune reconstitution of recipients after
allo-HSCT [22,23]. To explore whether intensified con-
ditioning affected EBV and CMV infections, we pro-
spectively studied the incidence and mortality of EBV
and CMV infections in the recipients of allo-HSCT fol-
lowing intensified or standard conditioning.
Methods
Patients
From February 2009 to December 2011, 189 consecutive
patients with hematological malignancies received allo-HSCT in our single institution. A total of 185 cases were
enrolled in this prospective study, and 4 cases who died
from regimen-related toxicity (RRT) or bacterial infec-
tion before hematopoietic reconstitution were not
included. The median age was 28.0 years (range 12–
63 years). Seventy-two patients were female, and 113
were male. The primary diseases included acute
leukemia (AL, n = 149), chronic myeloid leukemia
(CML, n = 28), lymphoma (n = 5), myelodysplastic syn-
drome (MDS, n = 2) and blastic plasmacytoid dendritic
cell neoplasm (n = 1). One hundred and twenty-five
patients were in the status of complete remission (CR)
(including patients with CML-chronic phase [CP]), and
60 were not in CR (NR) at the time of transplantation.
All recipients were EBV-DNA negative in blood and 99
were EBV-VCA (viral capsid antigen, IgG) seropositive
before transplantation. Two donors were EBV-DNA
positive and became EBV-DNA negative with antiviral
agents before collection of stem cells; 111 donors were
EBV-seropositive. Seven recipients and nine donors
were CMV-DNA positive in blood before transplant-
ation. After antiviral treatment, they were all CMV-
DNA negative at the time of transplantation. One hun-
dred and sixty-nine recipients and 171 donors were
CMV-IgG positive (Table 1). The study was performed
in accordance with the modified Helsinki Declaration,
and the protocol was approved by our ethical review
boards before study initiation. All recipients, donors
and/or guardians provided written informed consent.Conditioning regimens
Five conditioning regimens, including three standard
MA and two intensified MA conditioning regimens
were administrated. The standard conditioning was as
follows: ① TBI (4.5 Gy/day, -5, -4 days) +CY (60 mg/
kg/day, -3, -2 days) in 36 recipients; ② Bu (3.2 mg/kg/
day, -7 to −4 days) +CY (60 mg/kg/day, -3, -2 days) in
40 recipients; ③ Bu (3.2 mg/kg/day, -6 to −3 days) + Flu
(fludarabine, 30 mg/m2, -6 to −2 days) in 28 recipients.
The intensified conditioning included the following: ①
TBI (4.5 Gy/day, -5, -4 days) +CY+VP-16 (etoposide,
10–15 mg/kg/day, -3, -2 days) in 32 recipients; ② Flu
(30 mg/m2/day, -10 to −6 days) +Ara-C (cytarabine,
2.0 g/m2/day, -10 to −6 days) plus TBI (4.5 Gy/day, -5,
-4 days) +CY in 49 recipients [13]. The alternative rules
of conditioning depended on the high risk factors for
primary diseases and comorbidities at the time of trans-
plantation. Generally, except those with severe comor-
bidities, patients with high-risk genetics and/or in NR
at the time of transplantation all received intensified
conditioning; patients with intermediate/low-risk genet-
ics and in CR at the time of transplantation all received
standard conditioning (Table 1).
Table 1 Patient, donor and transplants characteristics





Female/Male 31(38.3%)/50(61.7%) 41(39.4%)/63(60.6%) NS
Median age, years (range) 26(14–54) 28(12–63) NS
Disease
ALL 42 (51.85%) 23 (22.1%) P<0.001
AML 17 (21.0%) 43(41.4%)
ALAL 12 (14.8%) 12 (11.5%)
CML 6 (7.4%) 22 (21.2%)
HD/NHL 3(3.7%) 2 (1.9%)
MDS 0 (0%) 2 (1.9%)
BPDCN 1 (1.25%) 0 (0%)
Disease status at the time of transplants
CR (including CML-CP) 31 (38.3%) 94 (90.4%) P<0.001
NR (including CML-AP and BC) 50 (61.7%) 10 (9.6%)
EBV serostatus










Sibling donor 44(54.3%) 73 (70.2%) P = 0.010
Family donor 11 (13.6%) 3 (2.9%)
Unrelated donor 26(32.1%) 28 (26.9%)
HLA typing
HLA-identical 49 (60.5%) 79 (76.0%) NS
One allele mismatched 15 (18.5%) 15 (14.4%)
Two alleles mismatched 8 (9.9%) 8 (7.7%)
Three alleles mismatched 1 (1.2%) 1 (0.95%)
Four alleles mismatched 6 (7.4%) 1 (0.95%)
Five alleles mismatched 2 (2.5%) 0 (0.0%)
Stem cell source
PBSCs 63 (77.8%) 90 (86.5%) NS
BM 1 (1.2%) 0 (0.0%)
PBSCs + BM 17(21.0%) 14 (13.5%)




TBI + CY 36 (34.6%) NA
Bu+CY 40 (38.5%)
Bu + Flu 28(26.9%)
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Table 1 Patient, donor and transplants characteristics (Continued)
Flu + Ara-c + TBI + CY 49 (60.5%)
TBI + CY+ VP-16 32 (39.5%)
GVHD prophylaxis
CsA 4 (5.0%) 2 (1.9%) NS
CsA+MTX 33 (40.75%) 62 (59.6%)
CsA+MTX+ATG 28 (34. 5%) 27 (26.0%)
CsA+MTX+MMF 3 (3.7%) 2 (1.9%)
CsA+MTX+ATG+MMF 13 (16.05%) 11 (10.6%)
ALL= acute lymphoblastic leukemia; AML= acute myelogenous leukemia; ALAL= acute leukemia of ambiguous lineage; CML= chronic myelogenous leukemia;
HD=Hodgkin’s disease; NHL=Non-Hodgkin’s lymphoma; MDS=myelodysplastic syndromes; BPDCN=blastic plasmacytoid dendritic cell neoplasm;CR= complete
remission; CP= chronic phase; NR=not in CR; AP= accelerated phase; BC=blastic crisis; D=donor; R= recipient; PBSCs=peripheral blood stem cells; BM=bone
marrow; TBI= total body irradiation; CY= cyclophosphamide; BU=busulfan; FLU= fludarabine; Ara-c= cytarabine; VP16= etoposide; GVHD=graft-versus-host
disease; CSA= cyclosporine A; MTX=methotrexate; ATG = antithymocyte globulin; MMF=mycophenolate mofetil; NS=not significant; NA=not applicable.
Xuan et al. Journal of Hematology & Oncology 2012, 5:46 Page 4 of 12
http://www.jhoonline.org/content/5/1/46Cyclosporine A (CsA) withdrawal and donor lymphocyte
infusion (DLI) in high-risk patients
According to the following criteria, CsA withdrawal
and/or DLI were conducted in all patients with acute
lymphoblastic leukemia (ALL) and high-risk factors
(high-risk genetics or NR/>CR2 [second complete remis-
sion] at the time of transplantation). Depending on
whether donor lymphocytes were available, CsA was
withdrawn in two ways in patients who did not experi-
ence acute GVHD (aGVHD) by day +30 post-transplant-
ation: if donor lymphocytes were unavailable, CsA was
withdrawn rapidly in a stepwise fashion (ie, total dose
reduced by 20%/week); if they were available, CsA was
withdrawn in a stepwise fashion (ie, total dose reduced
by 10%/week) and G-CSF mobilized donor lymphocytes
(1.0 × 108/kg, once a month, 4 doses totally) would be
infused in patients without II° or more than II° aGVHD
by day + 60 post-transplantation. Once patients devel-
oped GVHD after DLI, DLI would stop and methylpred-
nisolone was added to the regimen.
Prophylaxis and treatment for GVHD
CsA alone or CsA plus MTX (methotrexate) (on days +1
and +3) were administered in patients with NR undergo-
ing HLA-matched sibling donor transplantation, and
CsA plus MTX (on days +1, +3 and +6) were adminis-
tered in patients with CR undergoing HLA matched sib-
ling donor transplants for GVHD prophylaxis.
CsA +MTX+ATG (antithymocyte globulin, for total
doses of 6–10 mg/kg, on days −3 to −1 or −4 to 0) and/
or MMF (mycophenolate) were used in patients under-
going HLA-mismatched related and unrelated donor
transplants. Methylprednisolone (1–2 mg/kg/day) was
used to treat aGVHD. ATG or ATG combined with
CD25 monoclonal antibody and other immunodepres-
sants were used to treat glucocorticosteroid-resistant
aGVHD. Corticosteroids and CsA were used initially totreat chronic GVHD (cGVHD) and were used in com-
bination with various immunosuppressive agents to treat
cGVHD that was unresponsive to initial therapy.
Infection prophylaxis
Oral sulfamethoxazole and norfloxacin were given to
all patients. Acyclovir was given daily from the begin-
ning of conditioning therapy to engraftment, and it was
then administered daily for 7 days every 2 weeks until
1 year after transplantation. Ganciclovir was given for
2 weeks before transplantation for prophylaxis of CMV
infections, and was administered once again when
CMV viremia occurred. Antifungal agents were admi-
nistered 5 days before transplantation. Fluconazole
(0.3 g/day) or itraconazole (0.4 g/kg.d) was used for up
to +60 days post-transplantation in patients with no
history of invasive fungal infection (IFI); those with a
history of IFI received itraconazole (0.4 g/day), vorico-
nazole (0.4 g/day), caspofungin (50 mg/day) or Am-
Bisome (2 mg/kg.day) intravenously. Oral itraconazole
or voriconazole was started when the peripheral white
blood cell count exceeded 2.0 × 109/L and was discon-
tinued after 90 days post-transplantation.
Monitoring of EBV-DNA and CMV-DNA levels in blood
Generally, the EBV-DNA and CMV-DNA levels of blood
were monitored weekly for three months after trans-
plantation. During the 4th to 9th month post-transplant-
ation, the monitoring frequency was once every two
weeks; the 10th to the 24th month, once a month; the
25th to 36th month, once every three months. If EBV-
DNA or CMV-DNA was positive, it was monitored
twice a week.
The DNA levels of EBV and CMV in blood were
detected by quantitative real-time polymerase chain re-
action (RQ-PCR) [24,25]. The plasma (50 μl) was mixed
with 50 μl of nucleic acid extract, and the mixture was
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13000 rpm for 10 minutes. The supernatant was col-
lected for the next step. The PCR conditions for EBV
were as follows: 37°C for 2 mins and 94°C for 2 mins fol-
lowed by 40 cycles at 93°C for 15 s and 60°C for 1 min.
The sequences of the TaqMan probes and primers for
EBV were as follows: EBV TaqMan probe.
(FAM)-TCTGCTGTTGTTTCTGTCTCACCTACCGG-
(TAMRA); EBV forward primer, 5’-CCAGTGCTGT
GATCGAGCATCT-3’; and EBV reverse primer,
5’-CTGCTGACAAACTGCTGCATTC-3’. For CMV,
the PCR conditions were as follows: 1 cycle at 50°C
for 2 mins, 95°C for 10 mins and 45 cycles at 95°C for
15 s and 60°C for 1 min. The forward primer was
5’-GAAGGTGCAGGTGCCCTG-3’, the reverse primer 5’-
GTGTCGACGAACGACGTACG-3’ and the probe (FAM)-
ACGGTGCTGTAGACCCGCATACAAA-(TAMRA). The
normal threshold for EBV-DNA and CMV-DNA copies
in plasma provided by the manufacturer (ZJ Bio-Tech
Co.,Ltd., Shanghai, China) was less than 500 copies/ml.
EBV-DNA or CMV-DNA was considered positive when
the copies exceeded 500 copies/ml.
Intervention for EBV and CMV viremia
Once EBV-DNA or CMV-DNA in the blood was positive,
the viral loads would be detected once again the next
day. When EBV-DNA in the blood was positive twice
consecutively, several measures of control were taken, in-
cluding administration of antiviral agents (ganciclovir,
acyclovir or foscarnet), immunoglobulin (0.4 g/kg/d × 3d)
and reduction of immunosuppression if the condition of
the patient was acceptable. If EBV-DNA in the blood was
continuously positive four times with a rising trend, anti-
CD20 antibody (rituximab, 375 mg/m2) was administered
weekly until EBV-DNA was negative or for a total of
4 weeks.
When CMV-DNA in the blood was positive twice con-
secutively, ganciclovir or foscarnet was administrated. If
CMV-DNA in the blood was continuously positive four
times with a rising trend, several measures of control
were taken, including immunoglobulin (0.4 g/kg/d × 3d),
reduction of immunosuppression and the combination
of antiviral agents (ganciclovir and foscarnet).
Diagnosis of EBV-and CMV-associated diseases
EBV-associated diseases were classified into EBV-
associated post-transplant lymphoproliferative diseases
(PTLD) and EBV-associated other diseases. The diagno-
sis of EBV-associated PTLD was according to the criteria
of World Health Organization (WHO) [26,27]. The diag-
nosis of EBV-associated other diseases was based on the
criteria of the European Conference on Infections in
Leukemia and literatures [17,28,29], which included
EBV-associated fever without tissue involvement, EBV-associated diseases with tissue other than lymphatic tis-
sue involvement.
CMV-associated diseases were defined according to
published recommendations [15]. Briefly, CMV-associated
disease was defined by the presence of clinical symptoms
or signs of end organ disease, combined with the evidence
of CMV infection in a tissue biopsy specimen. CMV pneu-
monia was diagnosed on the basis of signs and symptoms
compatible with a diagnosis of pneumonia (hypoxemia,
x-ray) and a bronchoalveolar lavage (BAL) fluid or lung
biopsy specimen positive for CMV by immunohistology.
CMV gastrointestinal (GI) disease was diagnosed when GI
signs or symptoms occurred, and evidence of CMV in the
GI tract was diagnosed by immunohistochemistry or in
situ hybridization from biopsy specimens. CMV encephal-
itis was defined by the identification of central nervous
system symptoms together with the detection of CMV-
DNA in cerebrospinal fluid samples.
Once EBV- or CMV-associated diseases were consid-
ered or diagnosed, other viruses DNA including herpes
simplex virus (HSV) -types 1 and 2, adenovirus (ADV),
varicella zoster virus (VZV), human herpesvirus 6–8
(HHV6-8), parvovirus B19 and BK virus (BKV) were
detected in blood (VZV and parvovirus B19 were
detected by kit provided by ZJ Bio-Tech Co.,Ltd.,
Shanghai. HSV, ADV, HHV6-8 and BKV were detected
by kit provided by Huayin medical technology Co.,Ltd.,
Guangzhou.). BKV were measured using RQ-PCR
(Eppendorf AG, Hamburg, Germany), and other viruses
were measured using qualitative PCR.
Treatment of EBV- and CMV-associated diseases
Once EBV-associated diseases were diagnosed, several
measures would be taken promptly, including antiviral
agents, reduction of immunosuppression, rituximab,
combination chemotherapy, DLI and EBV-specific cyto-
toxic lymphocyte (EBV-CTL) treatment.
Once CMV-associated diseases were diagnosed,
several measures would also be taken promptly, in-
cluding administration of ganciclovir and foscarnet,
immunoglobulin (0.4 g/kg/d × 3d) and reduction of
immunosuppression.
Flow cytometry analysis
T lymphocyte subgroups (CD3+, CD3+CD4+, CD3+CD8+),
B lymphocytes (CD19+) and NK cells (CD16+ CD56+) in
peripheral blood of recipients were analyzed by flow
cytometry, respectively, at 1, 3 and 6 months after trans-
plantation. FITC-conjugated mouse anti-human CD3
(HIT3a), APC-conjugated anti-human CD4 (RPA-T4),
PE-conjugated anti-human CD8 (HIT8a), PerCP-Cy5.5-
conjugated anti-human CD19 (HIB19), PE-conjugated
anti-human CD16 (3 G8), PerCP-Cy5.5-conjugated
anti-human CD56 (B159) were purchased from BD
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incubated with FITC-, PE-, APC- and PerCP-Cy5.5-
conjugated mAbs or their isotype control Abs for
30 min at 4°C, followed by hemolysis liquid washing
and phosphate-buffered saline solution washing. All
samples were assayed by BD FACSCantoTM II (BD
Biosciences) and the acquired data were further ana-
lyzed using BD-FACSDiva Software. Flow cytometric
results were represented as percentage positive.Evaluation points and statistics
Our data was analyzed on May 31, 2012. The main
evaluation points included EBV and CMV infections
within 3 years post-transplantation as well as bac-
terial and fungal infections within 100 days post-
transplantation. The secondary evaluation points
included hematopoietic engraftment, primary disease
response, aGVHD, cGVHD, immune reconstitution,
recurrence and survival. Comparisons of categorical
variables were made by means of chi-squared and
Fisher exact tests for small numbers. Differences be-
tween numerical variables were calculated by means
of the Mann–Whitney U-test. Incidence of time-
dependent variables was estimated by the method of
Kaplan-Meier. Intervals were measured from the
day of transplantation until first diagnosis of EBV
or CMV infections or until the last day of follow-
up, transplant-related death or relapse. Univariate
and multivariate Cox regression models were used
to analyze risk factors for EBV and CMV infections
after transplantation as well as OS and DFS (dis-
ease-free survival). EBV and CMV infections as well
as OS and DFS were entered as time-dependent
covariates. Variables for the multivariate models
were selected with backward stepwise elimination
with significance exceeding 0.05 as the criterion for
removal from the models. A variable indicating
whether patients were in the intensified or standard
group was included in the models regardless of its
significance.Results
Patient, donor and transplants characteristics
The characteristics of patients, donors and transplants
are summarized in Table 1. There were significant dif-
ferences between standard and intensified group in
the category of diseases (P<0.001), disease status at
the time of transplantation (P<0.001) and donor type
(P = 0.010). As could be seen from the comparison,
more patients in the intensified group were cases with
ALL and/or in NR, receiving more family or unre-
lated donor transplants compared with standard
group.Hematopoietic engraftment and primary disease
response
Of the 189 consecutive patients undergoing transplant-
ation, 4 cases (3 in the intensified group, 1 in the stand-
ard group) died from RRT or bacterial infection before
hematopoietic reconstitution and were not included.
Regeneration of neutrophil counts > 0.5 × 109/L took a
median of 11 days (range 9–22 days) and 12 days
(range 9–31 days) in the standard and intensified group
(P= 0.486), respectively. Platelet counts > 20 × 109/L
were reached after a median of 12 days (range 9–
40 days) and 13 days (range 9–70 days) in the standard
and intensified group (P= 0.029), respectively. The sixty
patients in NR at the time of transplantation, including
50 cases in the intensified group and 10 in the standard
group, all achieved CR by day +30 post-transplantation.
CsA withdrawal and DLI
CsA was withdrawn in 42 (40.4%) cases in the standard
group and 50 (61.7%) in the intensified group according
to the criteria aforementioned (P= 0.004). 16.3% (17/
104) and 45.7% (37/81) cases received DLI in the stand-
ard and intensified group, respectively (P<0.001). Thirty-
eight cases who met the criteria of DLI did not receive
DLI because of the limitation of the donor lymphocytes
source, including 25 cases in the standard group and 13
in the intensified group (P= 0.182).
GVHD
Ninety-six cases developed aGVHD including 13 after
DLI; 80 of 164 cases surviving more than 100 days
developed cGVHD, including 20 after DLI. Grade I-IV
aGVHD occurred in 49 of 104 (47.1%) patients in the
standard group (grade I, n = 13; grade II, n = 29; grade
III, n = 5; grade IV, n = 2), compared with 47 of 81
(58.0%) cases in the intensified group (grade I, n = 8;
grade II, n = 28; grade III, n = 7; grade IV, n = 4)
(P= 0.141). cGVHD occurred in 43 of 94 (45.7%)
patients in the standard group (limited, n = 25; extensive,
n = 18), compared with 37 of 70 (52.9%) cases in the in-
tensified group (limited, n = 27; extensive, n = 10)
(P= 0.367). In order to rule out the effects of immuno-
suppressants withdrawal and DLI on GVHD, the inci-
dence of aGVHD I-IV and II- IV by day +30 was
compared in the two groups. Acute GVHD I-IV and II-
IV occurred in 31.7% (33/104) and 4.81% (5/104)
patients by day +30 post-transplantation in the standard
group, compared with 43.2% (35/81) and 12.3% (10/81)
cases in the intensified group (P= 0.108, P= 0.062,
respectively).
Infections within 100 days post-transplantation
Within the first 100 days post-transplantation, 101 cases
developed 150 episodes of infections. Comparing
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bacterial infections, 2 vs 5 had IFI, 9 vs 7 had viral infec-
tions except CMV and EBV viremia, 15 vs 22 had mixed
infections and 5 vs 3 had infections of unknown etiology.
The infection rates and the incidence of bacterial and
fungal infections within 100 days post-transplantation
were 49.0%, 32.7% and 11.5% in the standard group, com-
pared with 61.7%, 43.2% and 18.5% in the intensified group
(P=0.085, P=0.142, P=0.182, respectively). Eight cases
died of infections within 100 days post-transplantation, in-
cluding three who died of CMV-associated diseases and
two who died of EBV-associated diseases.
EBV viremia and EBV-associated diseases
With a median follow-up of 319 days post-transplantation
(range, 27 to 1194 days), 57 cases (30.4%) developed EBV
viremia and 28 (15.1%) developed EBV-associated dis-
eases including 16 EBV- PTLD and 12 EBV-associated
other diseases (7 EBV-associated fever, 1 encephalitis, 1
myelitis, 1 encephalitis with lung involvement, 1 enceph-
alitis with lung and liver involvement and 1 pneumonia).
EBV-associated diseases occurred in 2 (2%), 1 (50%) and 9
(34.6%) cases receiving transplants from matched siblingFigure 1 Cumulative incidence of EBV viremia (A), EBV-associated dis
cumulative incidence of EBV viremia and EBV-associated diseases were 25.3
45.6%± 6.5% and 26.0% ±5.3% in the intensified group (P= 0.002, P= 0.002
0.0%± 0.0% and 7.3%± 3.1% in the standard and intensified group, respectdonor, matched family donor and matched unrelated
donor; they occurred in 4 (23.5%), 4 (33.3%) and 8
(28.6%) cases from mismatched sibling donor, mis-
matched family donor and mismatched unrelated donor.
The median time to onset of EBV viremia and EBV-
associated diseases was 51 days (range, 22–368 days) and
63 days (range, 22–289 days) post-transplantation,
respectively.
EBV viremia occurred in 24 (23.1%) cases in the stand-
ard group and 33 (40.7%) cases in the intensified group
(P= 0.010). EBV-associated diseases occurred in 9 (8.7%)
cases in the standard group, including 4 EBV-associated
fever, 4 PTLD and 1 encephalitis with lung and liver in-
volvement; they occurred in 19 (23.5%) cases in the in-
tensified group, including 3 EBV- associated fever, 12
PTLD, 1 encephalitis, 1 myelitis, 1 encephalitis with lung
involvement and 1 pneumonia (P= 0.005). The 3-year
cumulative incidence of EBV viremia and EBV-
associated diseases were 25.3% ±4.6% and 10.5% ±3.4%
in the standard group, compared with 45.6%± 6.5% and
26.0% ±5.3% in the intensified group (P= 0.002,
P= 0.002, respectively, log-rank test, Figure 1A and 1B).
No case in the standard group and five cases in theeases (B) and mortality of EBV-associated diseases (C). The 3-year
% ±4.6% and 10.5% ±3.4% in the standard group, compared with
). The 3-year cumulative mortality of EBV-associated diseases was
ively (P= 0.008).
Figure 2 Cumulative incidence of CMV viremia (A), CMV-associated diseases (B) and mortality of CMV-associated diseases (C). The
3-year cumulative incidence of CMV viremia and CMV-associated diseases were 43.3%± 4.9% and 5.4%± 2.4% in the standard group, compared
with 48.1%± 7.1% and 6.9%± 3.0% in the intensified group (P= 0.855, P= 0.581). The 3-year cumulative mortality of CMV-associated diseases was
3.2%± 1.8% and 2.9%± 2.0% in the standard and intensified group, respectively (P= 0.933).
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3-year cumulative mortality of EBV-associated diseases
was 0.0% ± 0.0% and 7.3% ± 3.1% in the standard and in-
tensified group, respectively (P= 0.008) (Figure 1C).
CMV viremia and CMV-associated diseases
Seventy-seven cases (41.6%) developed CMV viremia
and 10 (4.9%) developed CMV-associated diseases in-
cluding 4 CMV pneumonia, 1 CMV encephalitis, 3
CMV enteritis, 1 CMV encephalitis together with enter-
itis as well as 1 CMV pneumonia together with enceph-
alitis. The median time to onset of CMV viremia and
CMV-associated diseases was 41 days (range, 11–
410 days) and 106 days (range, 45–198 days) post-trans-
plantation, respectively.
CMV viremia occurred in 43 (41.3%) cases in the
standard group and 34 (42.0%) cases in the intensified
group (P= 0.931). CMV-associated diseases occurred in
5 (4.8%) cases in the standard group and 5 (6.2%) cases
in the intensified group (P= 0.684). The 3-year cumula-
tive incidence of CMV viremia and CMV-associated dis-
eases were 43.3%± 4.9% and 5.4% ± 2.4% in the standard
group, compared with 48.1%± 7.1% and 6.9% ± 3.0% inthe intensified group (P= 0.855, P= 0.581, respectively,
log-rank test, Figure 2A and 2B). Three cases in the
standard group and two cases in the intensified group
died of CMV-associated diseases. The 3-year cumulative
mortality of CMV-associated diseases was 3.2%± 1.8%
and 2.9% ± 2.0% in the standard and intensified group,
respectively (P= 0.933) (Figure 2C).
Risk factors for EBV and CMV infections
Univariate and multivariate analysis about the risk fac-
tors for EBV and CMV infections are showed in Table 2.
On multivariate analysis, only use of ATG (relative risk
[RR] =15.554, 95% confidence interval [CI]: 6.598-
36.664, P<0.001; RR =19.216, 95% CI: 4.525-81.598,
P<0.001, respectively) and intensified conditioning regi-
mens (RR =1.759, 95% CI: 1.034-2.991, P= 0.037; RR
=2.290, 95% CI: 1.051-4.994, P= 0.037, respectively) were
the risk factors for EBV viremia and EBV-associated dis-
eases; HLA mismatch (RR =2.441, 95% CI: 1.551-3.840,
P<0.001) and early CsA withdrawal (RR =2.112, 95% CI:
1.307-3.412, P= 0.002) were the risk factors for CMV
viremia; aGVHDII-IV(RR =12.554, 95% CI: 1.570-
100.401, P= 0.017) was the only risk factor for CMV-
Table 2 Univariate and multivariate analyses of risk factors for EBV and CMV infections after allo-HSCT









male vs female NS NS NS NS NS NS NS NS
Age, <20 years vs ≥20 to≤ 40 years
vs > 40 years
NS NS NS NS NS NS NS NS
Disease status, CR vs NR P = 0.029 NS NS NS NS NS NS NS
Related vs unrelated donor P<0.001 NS P<0.001 NS NS NS NS NS
HLA typing, matched vs mismatched P<0.001 NS P<0.001 NS P<0.001 P<0.001 (2.441) NS NS
Standard vs intensified conditioning P = 0.002 P = 0.037
(1.759)
P = 0.006 P = 0.037
(2.290)
NS NS NS NS
EBV serological matches vs mismatches NS NS NS NS NS NS NS NS
CMV serological matches vs mismatches NS NS NS NS NS NS NS NS




P<0.001 NS P = 0.006 NS
Flu vs no Flu NS NS NS NS NS NS NS NS
Acute GVHD II-IV vs 0-I NS NS P = 0.032 NS P<0.001 NS P = 0.002 P = 0.017
(12.554)
Chronic GVHD vs no cGVHD NS NS NS NS NS NS NS NS
Early CsA withdrawal vs no early
withdrawal
NS NS NS NS P<0.001 P = 0.002
(2.112)
NS NS
DLI vs no DLI NS NS NS NS P = 0.010 NS NS NS
RR= relative risk; vs= versus; CR= complete remission; NR=not in CR; HLA= human leukocyte antigen; EBV= Epstein-Barr virus; CMV=Cytomegalovirus; ATG= anti-
thymocyte globulin; FLU= fludarabine; GVHD=graft-versus-host disease; CSA= cyclosporine A; DLI=donor lymphocyte infusion; NS=not significant.
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serological status, use of Flu and the occurrence of
cGVHD did not show any significant influence on the
risk of EBV and CMV infections.
Immune reconstitution
The total lymphocyte counts at 1, 3 and 6 months
after transplantation were (0.686 ± 0.453) × 109/L,
(1.463 ± 0.878) × 109/L and (1.512 ± 0.916) × 109/L in the
standard group, compared with (0.709 ± 0.390) × 109/L,
(1.237 ± 0.682) × 109/L and (1.566 ± 0.763) × 109/L in the
intensified group (P= 0.510, P= 0.082, P= 0.354, re-
spectively). The percentage of CD4+ T cells and ratio
of CD4+/CD8+ T cells in the standard group at
3 months post-transplantation were significantly
higher than that in the intensified group (P =0.032,
P =0.022). The percentages of CD3+ T cells, CD8+ T
cells, CD19+ B cells and CD16+ CD56+ NK cells at
3 months post-transplantation were similar between
standard and intensified group (all P>0.05). The per-
centages of all cell subsets at 1 and 6 months post-
transplantation did not differ significantly between
standard and intensified group (all P>0.05).
OS and DFS
With a median follow up of 10.6 months (range, 0.9 to
39.8 months), 117 cases were alive. Thirty-three cases inthe standard group and 35 in the intensified group died.
Comparing standard versus intensified regimens, the
causes of death included leukemia relapse (n = 18 vs 14),
GVHD (n= 7 vs 8), infections (n = 5 vs 7), RRT (n = 2 vs
0), EBV-associated diseases (n = 0 vs 5) and pulmonary
haemorrhage (n = 1 vs 1). The 3-year OS and DFS in the
standard group were 62.2%± 5.8% and 60.6%± 5.6%,
compared with 51.6%± 6.2% and 51.1% ± 5.9% in the in-
tensified group, respectively (P= 0.029, P= 0.063, log-
rank test). The 3-year cumulative incidence of relapse
and nonrelapse TRM were 28.1%± 5.7% and
18.1%± 4.8% in the standard group, compared with
38.2%± 8.9% and 27.8% ± 5.2% in the intensified group,
respectively (P= 0.209, P= 0.030, log-rank test).
Discussion
In allo-HSCT, the relapse of the underlying disease is
the main factor that affects survival. The intensity of
conditioning regimen has been shown to directly affect
the relapse and survival [30,31]. Some studies suggested
that intensified conditioning could reduce tumor relapse,
but it might simutaneously increase TRM including
infection-related mortality [10-12]. In addition to the
anti-tumor effect of conditioning regimens, the thera-
peutic efficacy of allo-HSCT also relies on the graft-
versus-tumor (GVT) effect [1,32]. In this study, based
on the results of our previous studies [13], we
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tapering of prophylactic immunosuppressants followed
by DLI for inducing GVT effect for patients with high-
risk and refractory hematological malignancies, with 3-
year OS and DFS of 51.6% ±6.2% and 51.1% ± 5.9%. The
results once again proven that intensified conditioning
followed by inducing GVT effect was effective for
patients with high-risk and refractory hematological
malignancies.
Infections are another leading cause of death after
allo-HSCT. Some studies reported that the incidence of
infections and the infection-related mortality might
reach up to 77% and 20% after allo-HSCT, respectively
[3,33,34]. Recently, with wide applications of antibacter-
ial and antifungal drugs in the prophylaxis and therapy
of infections, the incidence and mortality of bacterial
and fungal infections post-transplantation decrease
markedly. However, due to the absence of effective pre-
ventive and therapeutic drugs for most viruses, the inci-
dence and mortality of viral infections increase
relatively, especially in the early period after transplant-
ation. Some studies suggested that intensified condition-
ing was accompanied by an increasing incidence and
mortality of early-stage infections, due to aggravated tis-
sue and organ damage as well as the delay of immune
reconstitution after HSCT [10-12]. In this study, we pro-
spectively compared the effects of standard and intensi-
fied conditioning on infections, especially EBV and CMV
infections. Our data further confirmed our previous
results that intensified conditioning did not increase the
incidence and mortality of bacterial and fungal infec-
tions early post-transplantation [13]. Meanwhile, our
data showed that intensified conditioning might increase
the incidence of EBV viremia and EBV-associated dis-
eases as well as the mortality of EBV-associated diseases,
but it did not affect the incidence of CMV viremia and
CMV-associated diseases as well as the mortality of
CMV-associated diseases. The differences might be asso-
ciated with the fact that there was optimal strategy for
prevention and treatment of CMV infections, but lack of
effective methods to prevent and treat EBV infections.
Although EBV and CMV infections are the most com-
mon opportunistic viral infections and closely related to
the immune function, the risk factors for both infections
are different in recipients of allo-HSCT. Recognized
main risk factors for EBV infections include T-cell deple-
tion, use of ATG or anti-CD3 monoclonal antibody,
HLA mismatch, unrelated donor and so on [35-38]. Im-
portant risk factors for CMV infections are associated
with the serological status of donor and recipient,
aGVHD, T-cell depletion and use of ATG [18,23]. In this
study, we analyzed the risk factors for EBV and CMV
infections. Univariate analysis revealed that HLA mis-
match, unrelated donor, use of ATG, advanced diseasestatus and aGVHDII-IV were associated with EBV infec-
tions; use of ATG, aGVHDII-IV, HLA mismatch, early
CsA withdrawal and DLI were associated with CMV
infections. Upon multivariate analysis, use of ATG was
found to be the risk factor for EBV viremia and EBV-
associated diseases; HLA mismatch and early CsA with-
drawal were the risk factors for CMV viremia;
aGVHDII-IV was the only risk factor for CMV-
associated diseases. These results were consistent with
current studies [18,23,36,38], except the finding that
CMV infections was associated with early CsA with-
drawal and DLI. The reasonable explanation for this
finding was that early CsA withdrawal or DLI could in-
crease the incidence of GVHD, and GVHD was the risk
factor for CMV infections. Interestingly, univariate and
multivariate analysis both revealed that intensified con-
ditioning was the risk factor for EBV viremia and EBV-
associated diseases. The mechanisms that intensified
conditioning increased EBV infections might be asso-
ciated with the effects of intensified conditioning on
early immune reconstitution. Therefore, we analyzed the
immune reconstitution of recipients early post-
transplantation and found that the percentage of CD4+
T cells and ratio of CD4+/CD8+ T cells at 3 months
post-transplantation were significantly lower in the in-
tensified group.
Conclusions
Intensified conditioning represents a promising ap-
proach for high-risk hematological malignancies, al-
though it affects early immune reconstitution of
recipients and increases the incidence and mortality of
EBV infections.
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